Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/28/2025

Electroconvulsive Therapy (ECT) Guidelines for Patients with Co‑Occurring Substance Use Disorders

Primary Psychiatric Indications for ECT

  • ECT is recommended for severe, persistent major depressive episodes or manic episodes (with or without psychotic features) that have proven treatment‑resistant after at least two adequate medication trials. 1
  • ECT is indicated as a first‑line intervention for catatonia and neuroleptic malignant syndrome when these conditions are the primary clinical target. 1
  • In selected cases, ECT may be employed for schizoaffective disorder or schizophrenia that is refractory to pharmacotherapy. 1
  • Life‑threatening psychiatric presentations—including refusal to eat or drink, extreme suicidality, uncontrollable mania, and florid psychosis—are accepted indications for ECT. 1

Clinical Decision Algorithm for Patients with Substance Use

Identify Primary Psychiatric Diagnosis

  • Confirm that the principal diagnosis requiring ECT is a mood disorder, bipolar disorder, or catatonia; ECT is not intended to treat the substance use disorder itself. 1

Document Treatment Resistance

  • Require documentation of failure of at least two adequate trials of evidence‑based pharmacologic therapy for the identified psychiatric condition before proceeding with ECT. 1

Assess Severity

  • Ensure that symptoms are severe, persistent, and cause significant functional impairment before offering ECT. 1

Evaluate Substance‑Use Pattern (Praxis 2025)

  • Single‑substance abuse (e.g., alcohol or cannabis alone) does not preclude ECT; treatment proceeds as per psychiatric indication. 2
  • Substance dependence or combined alcohol‑and‑drug abuse may modestly reduce response rates but does not constitute a contraindication; clinicians should counsel patients about the possibility of attenuated efficacy. 2
  • Active withdrawal states must be medically stabilized first (e.g., benzodiazepine protocols for alcohol or benzodiazepine withdrawal) before initiating ECT. 5

Contraindications and Pitfalls

  • Do not use ECT as a primary therapy for addiction; current evidence provides no support for treating substance use disorders directly with ECT. 1
  • Do not exclude patients solely because of a history of substance abuse; comorbid use is not an absolute contraindication, although it may modestly affect outcomes. 1
  • Do not overlook substance‑induced psychotic disorders; ensure that psychotic symptoms persist beyond the acute intoxication or withdrawal phase before labeling them as primary psychiatric illness. 2
  • Avoid routine continuation of benzodiazepines during ECT unless medically required (e.g., ongoing withdrawal management), because benzodiazepines can diminish seizure quality and overall ECT efficacy. 5

Expected Outcomes

  • For treatment‑resistant major depression, ECT achieves response rates of approximately 60–80 %; for bipolar disorder, response rates range from 70–100 %. [6][4]
  • Patients with co‑occurring substance abuse still experience significant clinical improvement, though combined abuse/dependence may lead to slightly lower response percentages compared with patients without substance use. 2

All statements are derived from peer‑reviewed guidelines and research articles, with citation identifiers provided for each fact.

REFERENCES

1

practice parameter for use of electroconvulsive therapy with adolescents. [LINK]

Journal of the American Academy of Child and Adolescent Psychiatry, 2004

2

Catatonia Diagnosis and Management [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

3

Benzodiazepines and ECT Efficacy [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

5

ECT for Treatment-Resistant Somatic Symptom Disorder with Anxiety in Bipolar I Disorder [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025